Insulin resistance, obesity and metabolic syndrome in polycystic ovary syndrome;Resistencia a la insulina, obesidad y síndrome metabólico en el síndrome del ovario poliquístico

Endocrinologia y Nutricion

Volumn 53, Issue SUPPL. 1, 2006, Pages 41-55

  Gambineri, A ^a   Pasquali, R ^a  

^a UNIVERSITY OF BOLOGNA   (Italy)

Author keywords

Abdominal phenotype; Insulin resistance; Metabolic disorders; Obesity; PCOS

Indexed keywords

CLOMIFENE; INSULIN;

DISEASE ASSOCIATION; DISEASE PREDISPOSITION; DISEASE SEVERITY; ENVIRONMENTAL FACTOR; FEMALE INFERTILITY; GEOGRAPHIC DISTRIBUTION; GLUCOSE INTOLERANCE; HIGH RISK POPULATION; HUMAN; HYPERANDROGENISM; HYPERINSULINEMIA; INFERTILITY; INSULIN RESISTANCE; MENSTRUATION DISORDER; METABOLIC DISORDER; OBESITY; OVARY POLYCYSTIC DISEASE; OVULATION; PATHOPHYSIOLOGY; PHENOTYPE; PREVALENCE; REVIEW;

EID: 34347271262     PISSN: 15750922     EISSN: 15792021     Source Type: Journal    
DOI: 10.1016/S1575-0922(06)71168-8     Document Type: Article

References (69)

1. Gambineri A, Pelusi C, Vicennati V, Pagotto U, Pasquali R. Obesity and the polycystic ovary syndrome. Int J Obes Relat Metab Dis. 2002; 26: 883-96.
2. Dunaif A. Insulin resistance and the polycystic ovary syndrome: mechanisms and implications for pathogenesis. Endocr Rev. 1997;18:774-800.
3. Poretsky L, Cataldo NA, Rosenwaks Z, Giudice LC. The insulin-related ovarian regulatory system in health and disease. Endocr Rev. 1999;20:535-82.
4. Apridonidze T, Essah P, Iourno MJ, Nestler JE. Prevalence and characteristics of the metabolic syndrome in women with PCOS. J Clin Endocrinol Metab. 2005;90:1929-35.
5. Ehrmann DA. Polycystic ovary syndrome. N Engl J Med. 2005;352:1223-36.
6. Ehrmann DA, Sturis J, Byrne MM, Karrison T, Rosenfield RL, Polonsky KS. Insulin secretory defects in polycystic ovary syndrome. Relationship to insulin sensitivity and family history of non-insulin-dependent diabetes mellitus. J Clin Invest. 1995;96:520-7.
7. Wijeyartne CN, Balen AH, Barth JH, Belchetz PE. Clinical manifestation and insulin resistance (IR) in polycystic ovary syndrome (PCOS) among South Asians and Caucasians: is there a difference? Clin Endocrinol (Oxf). 2002;57:343-50.
8. Beck Nielsen H, Alford F, Hother-Nielsen O. Insulin resistance in glucose disposal and production in man with specific reference to metabolic syndrome and type 2 diabetes. En: Kumar S, O'Railly S, editors. Insulin resistance. New York: John Wiley & Sons; 2000. p. 155-78.
9. Bergman RN, Finegood DT, Ader M. Assessment of insulin sensitivity in vivo. Endocr Rev. 1985;6:45-86.
10. Mattews Dr, Hosker JP, Rudenski AS, Naylor BA, Treacher DF, Turner RC. Homeostasis model assessment: insulin resistance and B-cell function from fasting plasma glucose and insulin concentrations in man. Diabetologia. 1985;28:412-9.
11. Katz A, Nambi SS, Mater K, Baron AD, Follman DA, Sullivan G, et al. Quantitative insulin sensitivity check index: a simple, accurate method for assessing insulin sensitivity in humans. J Clin Endocrinol Metab. 2000;85:2402-10.
12. Dunaif A, Finegood DT. β-cell dysfunction independent of obesity and glucose intolerance in the polycystic ovary syndrome. J Clin Endocrinol Metab. 1996;81:942-7.
13. Reaven GM. The metabolic syndrome or the insulin resistance syndrome? Different names, different concepts, and different goals. Endocrinol Metab Clin North Am. 2004;33:283-303.
14. Carmina E, Lobo R. Use of fasting blood to assess the prevalence of insulin resistance in women with polycystic ovary syndrome. Fertil Steril. 2004;82:661-5.
15. Diamanti-Kandarakis E, Kouli C, Alexandraki K, Spina G. Failure of mathematical indices to accurately assess insulin resistance in lean, overweight, or obese women with polycystic ovary syndrome. J Clin Endocrinol Metab. 2004;89:1273-6.
16. Azziz JR, Sánchez LA, Knochenhauer ES, Moran C, Lazenby J, Stephens KC, et al. Androgen excess in women: experience with over 1000 consecutive patients. J Clin Endocrinol Metab. 2004;89:453-62.
17. Lewy VD, Danadian K, Witchel SF, Arslanian S. Early metabolic abnormalities in adolescent girls with polycystic ovarian syndrome. J Pediatr. 2001;138:38-44.
18. Gennarelli G, Roveri R, Novi F, Holte J, Bongiovanni F, Revelli A, et al. Preserved insulin sensitivity and β-cell activity, but decreased glucose effectiveness in normal weight women with polycystic ovary syndrome. J Clin Endocrinol Metab. 2005;90:3381-6.
19. Morin Papunen LC, Vahkonen I, Koivunen RM, Ruokonen A, Tapanainen JS. Insulin sensitivity, insulin secretion and metabolic and hormonal parameters in healthy women and women with polycystic ovary syndrome. Hum Reprod. 2004;15:1266-74.
20. Holte J, Bergh C, Berglund L, Litthell H. Enhanced early phase insulin response to glucose in relation to insulin resistance in women with polycystic ovary syndrome. J Clin Endocrinol Metab. 1994;78:1052-8.
21. Vrbikova J, Cibula D, Dvorakova K, Stanicka S, Sindelka G, Hill M, et al. Insulin sensitivity in women with polycystic ovary syndrome. J Clin Endocrinol Metab. 2004;89:2942-5.
22. Cibula D. Is insulin resistance an essential component of PCOS? Hum Reprod. 2004;19:757-9.
23. Pasquali R, Gambineri A, Anconetani B, Vicennati V, Colitta D, Caramelli E, et al. The natural history of the metabolic syndrome in young women with the polycystic ovary syndrome and the long-term effect of oestrogen-progestagen treatment. Clin Endocrinol (Oxf). 1999;50:517-27.
24. Gambineri A, Pelusi C, Manicardi E, Vicennati V, Cacciari M, Morselli-Labate AM, et al. Glucose intolerance in a large cohort of Mediterranean women with polycystic ovary syndrome. Phenotype and associated factors. Diabetes. 2004;53:2353-8.
25. Holte J, Bergh T, Berne C, Wide L, Lithell H. Restored insulin sensitivity but persistently increased early insulin secretion after weight loss in obese women with polycystic ovary syndrome. J Clin Endocrinol Metab. 1995;80:2586-93.
26. Stein IF, Leventhal ML. Amenorrhea associated with bilateral polycystic ovaries. Am J Obstet Gynecol. 1935;29:181-91.
27. Rogers J, Mitchell GW. The relation of obesity to menstrual disturbances. N Engl J Med. 1952;247:53-6.
28. Hartz AJ, Barboriak PN, Wong A, Katayama KP, Rimm AA. The association of obesity with infertility and related menstrual abnormalities in women. Int J Obesity Rel Metab Dis. 1979;3:57-77.
29. Pelusi C, Pasquali R. Polycystic ovary syndrome in adolescents. Pathophysiology and treatment implication. Treat Endocrinol. 2003;2:215-30.
30. Lake JK, Power C, Cole TJ. Women's reproductive health: the role of body mass index in early and adult life. Int J Obesity Rel Metab Dis. 1997;21:432-8.
31. The Rotterdam ESHRE/ASRM-Sponsored PCOS Consensus Workshop Group. Revised 2003 consensus on diagnostic criteria and long-term health risks related to polycystic ovary syndrome (PCOS). Hum Reprod. 2004;19:41-7.
32. Pasquali R, Gambineri A, Pagotto U. The impact of obesity on reproduction in women with polycystic ovary syndrome. Br J Obstet Gynecol. 2006. En prensa.
33. Lobo RA, Gysler M, March CM, Goebelman U, Mischell DR Jr. Clinical and laboratory predictors of clomiphene response. Fertil Steril. 1982;37:168-74.
34. Nestler JE, Jakubowicz DJ, Evans WS, Pasquali R. Effects of metformin on spontaneous and clomiphene-induced ovulation in the polycystic ovary syndrome. N Engl J Med. 1998;25:1876-80.
35. De Leo V, La Marca A, Petraglia F. Insulin-lowering agents in the management of polycystic ovary syndrome. Endocr Rev. 2003;24:633-7.
36. Filicori M, Flamigni C, Dellai P. Treatment of anovulation with pulsatile gonadotropin-releasing hormone: prognostic factors and clinical results in 600 cycles. J Clin Endocrinol Metab. 1994;79:1215-20.
37. White DM, Polson DW, Kiddy D, Sagle P, Watson H, Gilling-Smith C, et al. Induction of ovulation with low-dose gonadotropins in polycystic ovary syndrome: an analysis of 109 pregnancies in 225 women. J Clin Endocrinol Metab. 1996;81:3821-4.
38. Fedorcsák P, Dale PO, Storeng R, Tanbo T, Abyholm T. The impact of obesity and insulin resistance on the outcome of IVF or ICSI in women with polycystic ovarian syndrome. Hum Reprod. 2001;16:1086-91.
39. Ehrmann DA, Barnes RB, Rosenfield RL, Cavaghan MK, Imperial J. Prevalence of impaired glucose tolerance and diabetes in women with polycystic ovary syndrome. Diabetes Care. 1999;22:141-6.
40. Legro RS, Kunselman AR, Dodson WC, Dunaif A. Prevalence and predictors of risk for type 2 diabetes mellitus and impaired glucose tolerance in polycystic ovary syndrome: a prospective, controlled study in 254 affected women. J Clin Endocrinol Metab. 1999;84:165-9.
41. Weerakiet S, Srisombut C, Bunnag P, Sangtong S, Chuangsoongnoen N, Rojanasakul A. Prevalence of type 2 diabetes mellitus and impaired glucose tolerance in Asian women with polycystic ovary syndrome. Int J Gynaecol Obstet. 2001;75:177-84.
42. Legro RS, Gnatuk CL, Kunselman AR, Dunaif A. Changes in glucose tolerance over time in women with polycystic ovary syndrome: a controlled study. J Clin Endocrinol Metab. 2005;90:3236-42.
43. Kishore J, Harjai MBBS. Potential new cardiovascular risk factors: left ventricular hypertrophy, homocysteine, lipoprotein(a), triglycerides, oxidative stress, and fibrinogen. Ann Int Med. 1999;131:376-86.
44. Bloomgarden ZT. Inflammation and insulin resistance. Diabetes Care. 2003;26:1922-6.
45. Diamanti-Kandarakis E, Paterakis T, Alexandraki K, Piperi C, Aessopos A, Katsikis I, et al. Indices of low-grade chronic inflammation in polycystic ovary syndrome and the beneficial effect of metformin. Hum Reprod. 2006 [Epub ahead of print].
46. Kirschner MA, Samojlik E, Drejka M, Szmal E, Schneider G, Ertel N. Androgen estrogen metabolism in women with upper body versus lower body obesity. J Clin Endocrinol Metab. 1990;70:473-9.
47. Kurtz BR, Givens JR, Koinindir S, Stevens MD, Karas JG, Bitte JB, et al. Maintenance of normal circulating levels of Δ4androstenedione and dehydroepiandrosterone in simple obesity despite increased metabolic clearance rate: evidence for a servo-control mechanism. J Clin Endocrinol Metab. 1987;64:1261-7.
48. Azziz R. Reproductive endocrinologic alterations in female asymptomatic obesity. Fertil Steril. 1989;52:703-25.
49. Yen SSC. The polycystic ovary syndrome. Clin Endocrinol (Oxf). 1980;12:177-208.
50. Pasquali R, Casimirri F. The impact of obesity on hyperandrogenism and polycystic ovary syndrome in premenopausal women. Clin Endocrinol (Oxf). 1993;39:1-16.
51. Considine RV, Sinha MK, Heiman ML, Kriauciunas A, Stephens TW, Nyce MR. Serum immunoreactive leptin concentrations in normal-weight and obese humans. N Engl J Med. 1996;334:292-5.
52. Wiesner G, Vaz M, Collier G, Seals D, Kaye D, Jennings G, et al. Leptin is released from the human brain. Influence of adiposity and gender. J Clin Endocrinol Metab. 1999;84:2270-4.
53. Agarwal SK, Vogel K, Weitsman SR, Magoffin DA. Leptin antagonizes the insulin-like growth factor-I augmentation of steroidogenesis in granulosa and theca cells of the human ovary. J Clin Endocrinol Metab. 1999;84:1072-6.
54. Duggal PS, Van Der Hoek KH, Milner CR, Ryan NK, Armstrong DT, Magoffin DA, et al. The in vivo and in vitro effects of exogenous leptin on ovulation in rat. Endocrinology. 2000;141:1971-6.
55. Wajchenberg BL. Subcutaneous and visceral adipose tissue: their relation to the metabolic syndrome. Endocr Rev. 2000;21:697-738.
56. Pasquali R, Vicennati V. The abdominal obesity phenotype and insulin resistance are associated with abnormalities of the hypothalamic-pituitary- adrenal axis in humans. Horm Metab Res. 2000;32:521-5.
57. Masuzaki H, Paterson J, Shinyama H, Morton NM, Mullins JJ, Seckl JR, et al. A transgenic model of visceral obesity and the metabolic syndrome. Science. 2001;294:2166-70.
58. World Heath Organization. Definition, diagnosis and classification of diabetes mellitus and its complications. Part 1: diagnosis and classification of diabetes mellitus. Geneva: Department of Noncommunicable Disease Surveillance; 1999.
59. Balkau B, Charles MA, Comment on the provisional report from the WHO consultation. European Group for the Study of Insulin Resistance (EGIR). Diab Med. 1999;16:442-3.
60. Executive Summary of the Third Report of The National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol In Adults (Adult Treatment Panel III). JAMA. 2001;285:2486-97.
61. International Diabetes Federation. The IDF worldwide definition of the metabolic syndrome [citado 18 May 2005]. Disponible en: http://www.cdc.gov/nchs/ about/major/nhanes/nhanes/99-02.htm..
62. Glueck CJ, Papanna R, Wang P, Goldemberg N, Sieve-Smith L. Incidence and treatment of metabolic syndrome in newly referred women with confirmed polycystic ovarian syndrome. Metabolism. 2003;52:908-15.
63. Ehrmann DA, Liljenquist DR, Kasza K, Azziz R, Legro RS, Ghazzi MN, for the PCOS/Troglitazone Study Group. Prevalence and predictors of the metabolic syndrome in women with polycystic ovary syndrome. J Clin Endocrinol Metab. 2006;91:48-53.
64. Carmina E, Napoli N, Longo RA, Rini GB, Lobo RA. Metabolic syndrome in polycystic ovary sindrome (PCOS): lower prevalence in southern Italy than in the USA and the influence of criteria for the diagnosis of PCOS. Eur J Endocrinol. 2006;154:141-5.
65. Kohronen S, Hippelainen M, Vanhala M, Heinonen S, Niskanen L. The androgenic sex hormone profile is an essential feature of metabolic syndrome in premenopausal women: a controlled community-based study. Fertil Steril. 2003;79:1327-34.
66. Kahn R, Ferranini E, Buse J, Stern M. The metabolic syndrome: time for a critical rappraisal. Joint statement from the American Diabetes Association and the European Association for the study of Diabetes. Diabetes Care. 2005;28:2289-304.
67. Cheal KL, Abbasi F, Lamendola C, McLaughlin T, Reaven GM, Ford ES. Relationship to insulin resistance of the Adult Treatment Panel III Diagnostic Criteria for Identification of the Metabolic Syndrome. Diabetes. 2004;53:1195-200.
68. Greenfield MS, Doberne L, Kraemer F, Tobey T, Reaven GM. Assessment of insulin resistance with insulin suppression test and the euglycemic clamp. Diabetes. 1981;30:387-92.
69. Pasquali R, Gambineri A. Insulin resistance: definition and epidemiology in normal women and PCOS women. En: Diamanti-Kandarakis E, Nestler JE, Pasquali R, Panidis D, editors. Insulin resistance and polycystic ovarian syndrome: pathogenesis, evaluation, and treatment. Totowa: Humana Press; 2006.